Adaptive Biotechnologies Corp
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $277.0M
- Net income
- -$59.5M
- Total assets
- $512.7M
- Market cap
- $2.7B
- Gross margin
- 74.2%
- Operating margin
- -20.6%
- Net margin
- -21.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $277.0M
- Cost of revenue
- $71.4M
- Gross profit
- $205.6M
- Operating expenses
- $262.7M
- Operating income
- -$57.1M
- Income tax
- $0
- Net income
- -$59.5M
- EPS (basic)
- $-0.39
- EPS (diluted)
- $-0.39
Balance sheet
- Total assets
- $512.7M
- Current assets
- $300.2M
- Total liabilities
- $287.7M
- Current liabilities
- $89.9M
- Shareholders’ equity
- $225.0M
Cash flow
- Operating cash flow
- -$46.0M
- Investing cash flow
- $38.0M
- Financing cash flow
- $30.4M
- Net cash flow
- $22.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.7B
- EPS (diluted)
- $-0.39
- Shares outstanding
- 162.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 27, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $59.5M in FY2025.
- Revenue grew 182% from FY2020 to FY2025.
- Gross margin of 74.2%, net margin -21.5%.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Adaptive Biotechnologies Corp.
Write a review
News about Adaptive Biotechnologies Corp
News & sentiment via Polygon.io
